Clinical-stage oncology and rare disease therapeutics
Strategic Profile
The company is developing SUBA-Itraconazole for late-stage, metastatic castrate-resistant prostate cancer (mCRPC) and late-stage non-squamous non-small cell lung cancer (NSCLC). Inhibitor's business model centers on drug repurposing—licensing approved pharmaceuticals and obtaining patent-protected methods of use and delivery, enabling faster clinical development pathways compared to traditional novel drug discovery. This approach reduces development risk while leveraging well-characterized safety profiles.
Cyborg Score Rationale
Inhibitor operates in a challenging early-stage market with significant clinical and regulatory hurdles ahead. While the drug repurposing strategy offers advantages in safety data and potential faster approval timelines, the company remains in clinical development stages with proof-of-concept required for multiple indications. As a microcap OTC-traded company with limited public data on financial health, execution risk is elevated.
Top Insights
Drug repurposing model de-risks development by leveraging FDA-approved, well-characterized pharmaceuticals with known safety profiles
Pursuing multiple cancer indications (prostate cancer, lung cancer, Gorlin Syndrome) to diversify pipeline and reduce single-indication dependency
(March 2026) Provided clinical update on itraconazole program for Gorlin Syndrome with formulation and IP progress
(August 2024) Reported positive Phase 2b trial results for SUBA-Itraconazole in basal cell carcinoma nevus syndrome with 57.7% clinically meaningful tumor reduction rate
Named Competitors
Castration-resistant prostate cancer therapies — Established mCRPC treatment market leader
Non-small cell lung cancer therapies — Large pharma competitors in NSCLC immunotherapy space
Basal cell carcinoma treatments — Established Hedgehog pathway inhibitors for BCC/Gorlin Syndrome
Recent Developments
(March 2026) Clinical, formulation and IP update on itraconazole program for Gorlin Syndrome
(August 2024) Clinical development plan update with positive Phase 2b results for BCCNS treatment
(December 2023) Scientific Advisory Board announcement to guide clinical strategy
Open the full interactive Inhibitor Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.